News Quantified

MRK – merck & company, inc. (new) (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Boehringer Ingelheim launches AI centre in London [Yahoo! Finance]

Merck Says FDA Grants Priority Review to Keytruda-Padcev Combo for Bladder Cancer [Yahoo! Finance]

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer [Yahoo! Finance]

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer

Does EU Approval Of ENFLONSIA Reshape The Bull Case For Merck's Pipeline Story (MRK)? [Yahoo! Finance]

3.0%

BEAT

2.5%

BEAT

-5.0%

BEAT

0.8%

BEAT

Royal Bank Of Canada

Royal Bank Of Canada

Form ARS Merck & Co., Inc. For: Dec 31

Form DEFA14A Merck & Co., Inc.

Form DEF 14A Merck & Co., Inc. For: May 26

Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Seidman Christine E

Form 4 Merck & Co., Inc. For: Mar 31 Filed by: GLOCER THOMAS H

Top News Gainers

3/28 Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies 7.5%

3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%

3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%

3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%

3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%

4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%

4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%

10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%

10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%

1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%

Top News Decliners

3/13 Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily] -8.6%

3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%

2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%

4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%

9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%

4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%

4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%

7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%

3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%

8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day